(May 5, 2015) Data from a large clinical trial shows that a personalized method for interpreting blood tests identifies more ovarian cancer cases than a generalized approach. The results from the study will be published in the Journal of Clinical Oncology. Using an algorithm to analyze changes in the level of CA-125 (a protein in … Continued
(April 29, 2015) A study published in JAMA Oncology last Saturday concluded that an oophorectomy, the surgery to remove ones ovaries, has a substantial impact on survival rates for those diagnosed with stage I or II breast cancer who also tested positive for the BRCA1 mutation. Involved in the study were 676 women, 345 of whom had … Continued
On April 23, the drug manufacturer Mylan N.V. announced a voluntary nationwide recall of select lots of several drugs used in the treatment of ovarian cancer. The nationwide recall includes several formulations of injectable gemcitabine and cytarabine. While no adverse events have been reported with the use of these drugs, patients who may be experiencing problems related to these drugs should contact their physicians. Expand the post for more information about the recall.
Ovarian Cancer Research Fund, Ovarian Cancer National Alliance and National Ovarian Cancer Coalition Team-Up to Fund Game-Changing Ovarian Cancer Research Today the members of the new Stand Up To Cancer-Ovarian Cancer Research Fund-Ovarian Cancer National Alliance-National Ovarian Cancer Coalition Translational Research Dream Team were announced. The Dream Team will focus on “DNA Repair Therapies for … Continued
April 20, 2015: The Ovarian Cancer Dream Team has been chosen! The Dream Team will focus on “DNA Repair Therapies for Ovarian Cancer,” building on recent advances that have identified DNA repair as a common weakness in ovarian cancer. Researchers will also explore the prevention and early detection of ovarian cancer by developing a … Continued
(April 16, 2015) The Society of Gynecologic Oncology has published recommendations for prevention of ovarian cancer in Cancer. Strategies include oral contraceptive use and tubal sterilization, as well as genetic counseling and testing for women from high-risk families. Read the abstract in ACS Journals.
(April 15, 2015) Doctors have long recognized that women with mutations in two particular genes – BRCA1 and BRCA2 – have a higher risk of breast and ovarian cancer. Now they are starting to figure out which mutations are worse than others. They have even discovered that some of these mutations may reduce a woman’s … Continued
(April 14, 2015) The FDA granted breakthrough therapy designation to rucaparib as monotherapy for patients with advanced ovarian cancer. Rucaparib is an oral, small-molecule PARP inhibitor developed for the treatment of platinum-sensitive ovarian cancer, specifically in patients with tumors that have BRCA mutations and other DNA deficiencies commonly referred to as “BRCA-like.” An FDA-designated “breakthrough … Continued
We are now accepting letters of intent for all research grants. LOIs are due May 8, 2015. Click here for more information.
(April 2, 2015) According to a study published in the journal Oncogene, the tumor microenvironment can regulate tumor suppressor miRNA in ovarian cancer cells. The direct interaction of the ovarian cancer cells with mesothelial cells, which cover the surface of the omentum, caused methylation mediated decrease in the expression of miR-193b in the tumor cells. … Continued
(April 1, 2015) A study published in Cancer Epidemiology, Biomarkers and Prevention looks at ovarian cancer risk in the general population. In U.S. women, lifetime risk of ovarian cancer is 1.37%, but some women are at a substantially lower or higher ovarian cancer risk due to both genetic and lifestyle factors. Leigh Pierce, PhD and … Continued
(March 27, 2015) According to research published this week in the Journal of Clinical Oncology, intraperitoneal (IP) chemotherapy is associated with a long-term survival advantage in ovarian cancer. The advantage of IP over intravenous chemotherapy extends beyond 10 years, and IP therapy enhanced survival of those with gross residual disease. Survival improved with increasing number … Continued
Get email updates about research news, action alerts, and ways to join the fight.
A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
